Supernus Pharmaceuticals Inc (SUPN) Shares Sold by Bruce & Co. Inc.

Bruce & Co. Inc. trimmed its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 88.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 178,058 shares of the specialty pharmaceutical company’s stock after selling 1,356,523 shares during the period. Supernus Pharmaceuticals makes up about 1.6% of Bruce & Co. Inc.’s portfolio, making the stock its 18th largest holding. Bruce & Co. Inc. owned 0.35% of Supernus Pharmaceuticals worth $7,122,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after acquiring an additional 984,200 shares during the last quarter. Pictet Asset Management Ltd. lifted its position in shares of Supernus Pharmaceuticals by 438.7% during the 3rd quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock valued at $19,651,000 after acquiring an additional 400,083 shares during the last quarter. Scout Investments Inc. lifted its position in shares of Supernus Pharmaceuticals by 239.5% during the 3rd quarter. Scout Investments Inc. now owns 565,900 shares of the specialty pharmaceutical company’s stock valued at $22,636,000 after acquiring an additional 399,225 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter valued at $10,646,000. Finally, Royal Bank of Canada lifted its position in shares of Supernus Pharmaceuticals by 790.8% during the 2nd quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock valued at $11,699,000 after acquiring an additional 240,978 shares during the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $38.15 on Wednesday. Supernus Pharmaceuticals Inc has a one year low of $22.25 and a one year high of $50.04. The stock has a market cap of $1,945.40, a price-to-earnings ratio of 35.80, a price-to-earnings-growth ratio of 1.61 and a beta of 1.19.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals’s revenue for the quarter was up 41.5% on a year-over-year basis. equities research analysts anticipate that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current year.

A number of equities research analysts have recently commented on SUPN shares. Cowen reiterated a “buy” rating and set a $50.00 price objective on shares of Supernus Pharmaceuticals in a research report on Thursday, September 21st. Jefferies Group reissued a “buy” rating and set a $51.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. FBR & Co began coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $53.00 target price on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. Finally, BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $49.60.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.truebluetribune.com/2017/12/13/supernus-pharmaceuticals-inc-supn-shares-sold-by-bruce-co-inc.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply